Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Revenue Performance and Segment Results
CRL logo

Charles River Laboratories Expands Operating Margins to 12% Amid Strategic $405 Million Acquisition

CRL10-QFiling Date: 5/7/2026
Charles River Laboratories International, Inc.
Description

What this story covers

Charles River Laboratories navigated a cautious spending environment in the first quarter of 2026, achieving 1.2% revenue growth and significant margin expansion through restructuring. Key moves included a 405 million dollar NHP supplier acquisition and a 118 million dollar divestiture of CDMO assets.

Story snapshot

CompanyCharles River Laboratories International, Inc.
TickerCRL
VariantStandard detailed
Duration12:37
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001100682-26-000038
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in